Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib ± tislelizumab in advanced solid tumors
CTR20182363Phase 2Completed
- Sponsor
- Catalent
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitravatinib, tislelizumab in hepatocellular carcinoma (HCC), gastric cancer (GC), esophagogastric junction cancer, Nonhematologic neoplasms, sponsored by Catalent. Started Dec 2018; status: completed.
02
Drugs
sitravatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)esophagogastric junction cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20182363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182363.